I disagree—right now the primary overhang on Amarin Corporation is absolutely legal uncertainty. Revenue growth, partnerships, and ex-U.S. expansion all depend on one core issue: whether the U.S. market is structurally protected or permanently impaired by generics. As long as that question is unresolved, institutions will stay cautious because they can’t confidently model future cash flows.
If Amarin prevails, it’s not just a “short-term bounce.” It fundamentally changes the landscape—generic pressure in the CV space would pull back, pricing power improves, prescriptions shift, and the U.S. revenue base can expand materially. On top of that, potential damages from Hikma add another layer of upside. That’s not cosmetic—that’s a full reset of the commercial trajectory and narrative—and a real opportunity to rectify the Du-era disaster.
So yes, revenue matters—but legal clarity is the gatekeeper to that revenue. Remove the legal overhang, and everything else—growth, institutional interest, valuation—can finally re-rate in a meaningful way.
Market Data 
Markets 
AI
